Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG-siRNAMETTL17
- Development stage
- Preclinical
- Lead developer
- City of Hope
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
**CpG-siRNAMETTL17** is a preclinical, TLR9-targeted oligonucleotide conjugate developed to silence **METTL17** in acute myeloid leukemia. It links a METTL17-directed small interfering RNA to the CpG-D19 oligodeoxynucleotide, a Toll-like receptor 9 ligand intended to promote uptake by TLR9-positive immune cells, including AML cells. METTL17 knockdown reduces mitochondrial 12S rRNA methylation and stability, impairs mitochondrial protein synthesis and oxidative phosphorylation, and suppresses leukemia stem-cell maintenance and AML growth in experimental models. ([ash.confex.com](https://ash.confex.com/ash/2024/webprogram/Paper201916.html))
- Other names
- CpG-siRNAMETTL17CpG-siRNAMETTL-17CpG-siRNAMETTL 17
02
Targets
TLR9 (Toll-like receptor 9)METTL17 (Methyltransferase-like protein 17)
Beyond the preview
Go deeper on CpG-siRNAMETTL17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CpG-siRNAMETTL17.